TOP PAGE
ENGLISH
JAPANESE
|
CONNECT WITH US:
Home
About
Services
Contact
Log in
*
Home
Press release
May 20, 2021 14:36 JST
Source:
Apollomics, Inc.
APOLLOMICS INC. ANNOUNCES OFFICIAL OPENING OF SHANGHAI BRANCH
Foster City, CA, Shanghai and Hangzhou, China, May 20, 2021 - (ACN Newswire) - Apollomics Inc., an innovative biopharmaceutical company committed to the discovery and development of mono- and combination- oncology therapies, today announced that Apollomics Shanghai Branch has been officially opened and started its operations at Zhangjiang Hi-Tech Park, Pudong District, Shanghai.
Dr. Guoliang Yu, the company's Co-Founder, Chairman and CEO said, "In 2018, we established a Chinese company in Hangzhou, and our Chinese team has grown from a few people to dozens of people. The Shanghai branch is located in the Silicon Valley of bioinnovative drugs in China, Zhangjiang Medicine Valley, which has gathered top talent from research and development, clinical and commercialization. Many of our clinical trials in China are soon to be carried out. The establishment of the Shanghai branch will be more conducive to the construction of our diverse talent team and will also promote connection and communication with domestic and foreign partners."
About Apollomics, Inc.
Apollomics, Inc. is an innovative biopharmaceutical company committed to the discovery and development of monotherapies and combination therapies of tumor-targeting agents and immuno-oncology agents. It has operating entities in Foster City, California, USA and Hangzhou, China. The company's product pipeline has many projects at different stages of development, including novel, humanized monoclonal antibodies that restore the body's immune system to recognize and kill cancer cells, and targeted therapies against uncontrolled growth signaling pathways. For more information, please visit www.apollomicsinc.com.
Contact information of Apollomics:
Investor Contact:
Wilson W. Cheung
Chief Financial Officer
Telephone: +1-650-209-4436
Email:
wcheung@apollomicsinc.com
Company Contact:
Liping Zhang
Telephone: +86-571-83521933
Email:
liping.zhang@apollomicsinc.com
U.S. Media Contact:
Remy Bernarda
Corporate Communications
(415) 203-6386
remy.bernarda@apollomicsinc.com
China Media Contact:
Porda Havas International Finance Communications Group
Kelly Fung
General Manager
Telephone: (852) 3150 6763
Email:
kelly.fung@pordahavas.com
Phoenix Fung
Assistant Vice President
Telephone: (852) 3150 6773
Email:
phoenix.fung@pordahavas.com
Source: Apollomics, Inc.
Sectors: BioTech, Healthcare & Pharm
Copyright ©2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
Related Press Release
Apollomics, a Company Developing Novel Oncology Therapies to Address Difficult-to-Treat Cancers, Announces Closing of Business Combination and Listing on Nasdaq
March 30 2023 20:29 JST
Apollomics Inc. Expands Leadership Team with Appointment of Jane Wang, PhD as Chief Scientific Officer
July 26 2022 09:17 JST
Apollomics Inc. to Host Virtual Investor Events on Wednesday, January 26, 2022 and Thursday, January 27, 2022
January 12 2022 09:25 JST
Apollomics Inc. Announces CEO Guo-Liang Yu, PhD Appointed as Chairman of the Board for the BayHelix Group
January 04 2022 10:10 JST
Apollomics Inc. Doses First Patient in Phase 3 Clinical Trial with APL-106 (Uproleselan Injection) in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia
November 22 2021 10:40 JST
Edison Oncology and Apollomics Announce Treatment of First Patient by EO1001 (APL-122) in a Phase I/IIa Clinical Trial
October 01 2021 10:00 JST
Apollomics, Inc. Doses First Patient in a Phase I Clinical Trial of APL-102
August 10 2021 11:53 JST
Apollomics, Inc. Appoints Seasoned Healthcare Executive K. Peony Yu, M.D., as Chief Medical Officer
March 09 2021 10:35 JST
Apollomics, Inc Announces Enrollment of First Patient in Phase 1 Clinical Trial of APL-106 (uproleselan injection) in China
March 04 2021 11:30 JST
Apollomics, Inc. Licenses a Targeted, Active Checkpoint Control Immunotherapy for Greater China and South Africa
February 12 2021 13:00 JST
More Press release >>
Latest Press Release
Honda Running Team Member, Nagiya Mori, Selected to Represent Japan in World Athletics Championships Tokyo 25 (WCH Tokyo 25) Men's 5000m Event
Sep 03, 2025 12:30 JST
Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status
Sep 03, 2025 11:32 JST
Anime Tokyo Station: TV Anime "SPY x FAMILY" Special Exhibition, Period: August 16 - November 9, 2025
Sep 03, 2025 11:00 JST
Fujitsu, 1Finity and Arrcus sign strategic partnership agreement to deliver innovative network solutions for AI infrastructure
Sep 03, 2025 10:58 JST
Mitsubishi Corporation Invests in Commonwealth Fusion Systems, a US Fusion Energy Start-up from MIT
Sep 02, 2025 12:50 JST
Hitachi has been certified as a Gold Partner of Scaled Agile, Inc., the provider of the large-scale agile framework "SAFe(R)"
Sep 02, 2025 11:50 JST
ABVC BioPharma Receives $450,000 in Licensing Payments from OncoX BioPharma in Q3 2025
Sep 01, 2025 22:28 JST
DENSO Signs Agreement to Transfer Part of Its Ceramic Product Business
Sep 01, 2025 20:52 JST
Honda to Provide Official Vehicles for World Athletics Championships Tokyo 25 as Official Global Partner
Sep 01, 2025 13:50 JST
FDA Approves LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease
Sep 01, 2025 13:44 JST
TANAKA Memorial Foundation to Offer Precious Metals Research Grants of Up to 10 Million Yen (from a Grant Pool of 20 Million Yen) - Applications for Research Projects Open on September 1
Sep 01, 2025 11:00 JST
ABVC BioPharma Receives $450,000 in Licensing Payments from OncoX BioPharma in Q3 2025
Aug 29, 2025 20:39 JST
Honda Announces New Plan for Relocation of Global Head Office to Yaesu Area in Tokyo and Reconstruction of Honda Aoyama Building
Aug 29, 2025 18:54 JST
Ministry Of Health, Labour and Welfare Grants Orphan Drug Designation in Japan to Anticancer Agent Tazemetostat for Unresectable INI1-Negative Epithelioid Sarcoma
Aug 29, 2025 18:17 JST
Hitachi Energy acquires remaining stake of eks Energy, reinforcing leadership in power conversion systems for energy storage
Aug 29, 2025 15:17 JST
Hong Kong Watch & Clock Fair, Salon de TIME return in September
Aug 28, 2025 21:27 JST
SenseTime Announces 2025 Interim Results
Aug 28, 2025 21:20 JST
Ausnutria 2025 Interim Results Announcement: Revenue and Profit Maintain Resilient Dual Growth
Aug 28, 2025 19:09 JST
Baguio Green Group (1397.HK) Announces 2025 Interim Results
Aug 28, 2025 19:03 JST
Production, Sales and Export Results for July, 2025
Aug 28, 2025 17:36 JST
More Latest Release >>